Latest Earnings Results: Q3 '26
Estimated EPS
-$0.08
Reported EPS
$0.23
Surprise
+376%
Estimated Rev
$1.02B
Reported Rev
$1.02B
Surprise
+0.22%
• Reported GAAP EPS of $0.23 up 91.67% YoY • Reported revenue of $1.02B up 32.02% YoY • BioMarin updated FY2026 guidance to total revenues of $3.8B, Metabolic Conditions $2.68B, VOXZOGO $975M, and Non-GAAP Diluted EPS $2.80 to $3.10.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $0.82 | -- | -- | N/A |
Q3 '26 | -$0.08 | $0.23 | 376.00% | BEAT |
Q2 '26 | $0.95 | $1.20 | 26.98% | BEAT |
Q1 '26 | $0.69 | $0.76 | 9.59% | BEAT |
Q4 '25 | $0.17 | -$0.24 | -241.66% | MISSED |